Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
157M
-
Number of holders
-
301
-
Total 13F shares, excl. options
-
101M
-
Shares change
-
-2.65M
-
Total reported value, excl. options
-
$2.36B
-
Value change
-
-$22.9M
-
Put/Call ratio
-
0.73
-
Number of buys
-
182
-
Number of sells
-
-112
-
Price
-
$23.39
Significant Holders of TG THERAPEUTICS, INC. - Common Stock (TGTX) as of Q3 2024
370 filings reported holding TGTX - TG THERAPEUTICS, INC. - Common Stock as of Q3 2024.
TG THERAPEUTICS, INC. - Common Stock (TGTX) has 301 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 101M shares
of 157M outstanding shares and own 64.17% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (22M shares), VANGUARD GROUP INC (15.4M shares), STATE STREET CORP (9.09M shares), Pictet Asset Management Holding SA (3.58M shares), GEODE CAPITAL MANAGEMENT, LLC (3.21M shares), Woodline Partners LP (2.57M shares), GOLDMAN SACHS GROUP INC (2.56M shares), Soleus Capital Management, L.P. (2.53M shares), Opaleye Management Inc. (2.28M shares), and MORGAN STANLEY (2.16M shares).
This table shows the top 301 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.